Julie Hambleton - Net Worth and Insider Trading
Julie Hambleton Net Worth
The estimated net worth of Julie Hambleton is at least $209,264 dollars as of 2024-11-29. Julie Hambleton is the Director of SpringWorks Therapeutics Inc and owns about 4,095 shares of SpringWorks Therapeutics Inc (SWTX) stock worth over $170,884. Julie Hambleton is the Director of IGM Biosciences Inc and owns about 2,000 shares of IGM Biosciences Inc (IGMS) stock worth over $20,860. Julie Hambleton is also the Director of Erasca Inc and owns about 6,000 shares of Erasca Inc (ERAS) stock worth over $17,520. Details can be seen in Julie Hambleton's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Julie Hambleton has not made any transactions after 2024-07-25 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Julie Hambleton
Julie Hambleton Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Julie Hambleton owns 5 companies in total, including SpringWorks Therapeutics Inc (SWTX) , IDEAYA Biosciences Inc (IDYA) , and IGM Biosciences Inc (IGMS) among others .
Click here to see the complete history of Julie Hambleton’s form 4 insider trades.
Insider Ownership Summary of Julie Hambleton
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| SWTX | SpringWorks Therapeutics Inc | 2024-06-03 | director |
| IDYA | IDEAYA Biosciences Inc | 2019-05-22 | SVP & Chief Medical Officer |
| IGMS | IGM Biosciences Inc | 2024-07-25 | director |
 | | 2015-11-11 | EVP & Chief Medical Officer |
| | 2021-07-20 | director |
Julie Hambleton Latest Holdings Summary
Julie Hambleton currently owns a total of 3 stocks. Among these stocks, Julie Hambleton owns 4,095 shares of SpringWorks Therapeutics Inc (SWTX) as of June 3, 2024, with a value of $170,884 and a weighting of 81.66%. Julie Hambleton owns 2,000 shares of IGM Biosciences Inc (IGMS) as of July 25, 2024, with a value of $20,860 and a weighting of 9.97%. Julie Hambleton also owns 6,000 shares of Erasca Inc (ERAS) as of July 20, 2021, with a value of $17,520 and a weighting of 8.37%.
Latest Holdings of Julie Hambleton
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| SWTX | SpringWorks Therapeutics Inc | 2024-06-03 | 4,095 | 41.73 | 170,884 |
| IGMS | IGM Biosciences Inc | 2024-07-25 | 2,000 | 10.43 | 20,860 |
| ERAS | Erasca Inc | 2021-07-20 | 6,000 | 2.92 | 17,520 |
Holding Weightings of Julie Hambleton
Julie Hambleton Form 4 Trading Tracker
According to the SEC Form 4 filings, Julie Hambleton has made a total of 3 transactions in SpringWorks Therapeutics Inc (SWTX) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in SpringWorks Therapeutics Inc is the sale of 4,648 shares on June 3, 2024, which brought Julie Hambleton around $186,059.
According to the SEC Form 4 filings, Julie Hambleton has made a total of 2 transactions in IGM Biosciences Inc (IGMS) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in IGM Biosciences Inc is the sale of 15,132 shares on July 25, 2024, which brought Julie Hambleton around $211,848.
According to the SEC Form 4 filings, Julie Hambleton has made a total of 1 transactions in Erasca Inc (ERAS) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Erasca Inc is the acquisition of 6,000 shares on July 20, 2021, which cost Julie Hambleton around $96,000.
Insider Trading History of Julie Hambleton
- 1
Julie Hambleton Trading Performance
GuruFocus tracks the stock performance after each of Julie Hambleton's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Julie Hambleton is 20.84%. GuruFocus also compares Julie Hambleton's trading performance to market benchmark return within the same time period. The performance of stocks bought by Julie Hambleton within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Julie Hambleton's insider trading performs compared to the benchmark.
Performance of Julie Hambleton
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -6.38 | | | | | |
| Relative Return to S&P 500(%) | -7.41 | | | | | |
Julie Hambleton Ownership Network
Julie Hambleton Owned Company Details
What does SpringWorks Therapeutics Inc do?
Who are the key executives at SpringWorks Therapeutics Inc?
Julie Hambleton is the director of SpringWorks Therapeutics Inc. Other key executives at SpringWorks Therapeutics Inc include director & Chief Executive Officer Saqib Islam , Chief Business Officer Badreddin Edris , and Chief People Officer Daniel Pichl .
SpringWorks Therapeutics Inc (SWTX) Insider Trades Summary
Over the past 18 months, Julie Hambleton made 3 insider transaction in SpringWorks Therapeutics Inc (SWTX) with a net sale of 9,466. Other recent insider transactions involving SpringWorks Therapeutics Inc (SWTX) include a net sale of 98,000 shares made by Saqib Islam , a net sale of 41,181 shares made by Daniel Pichl , and a net sale of 40,000 shares made by Badreddin Edris .
In summary, during the past 3 months, insiders sold 69,000 shares of SpringWorks Therapeutics Inc (SWTX) in total and bought 0 shares, with a net sale of 69,000 shares. During the past 18 months, 196,703 shares of SpringWorks Therapeutics Inc (SWTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 196,703 shares.
SpringWorks Therapeutics Inc (SWTX)'s detailed insider trading history can be found in Insider Trading Tracker table.
SpringWorks Therapeutics Inc Insider Transactions
Julie Hambleton Mailing Address
Above is the net worth, insider trading, and ownership report for Julie Hambleton. You might contact Julie Hambleton via mailing address: C/o Five Prime Therapeutics, Inc., Two Corporate Drive, South San Francisco Ca 94080.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
